ArriVent

formerly ArriVent BioPharmaIPO

Home - ArriVent BioPharma

ArriVent is a biotech company in Newtown Square, United States, founded in 2021. It has raised $305.0M across 2 rounds, most recently a $155.0M Series B in March 2023.

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$305.0M
Last Round
$155.0M Series BMar 2023
Rounds
2
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 20 investors for this company. to use credits for reveals, or explore the API.

About

ArriVent BioPharma was founded in 2021 to identify, develop, and commercialize differentiated medicines from around the world — particularly innovative therapies initially developed in China, Europe, South Korea, and Japan that might not otherwise reach global patients. The company applies deep oncology expertise and regulatory knowledge to in-license clinical-stage candidates with strong biological rationale and a clear path to approval.

Funding & Exit History

Data from Indexed.vcUpdated
Secondary MarketSecondary MarketJul 2025

4 more events

  • IPO2024
  • IPO2024
  • Series B202317 investors

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Marketing & SEO ×2
  • Cloud/Infrastructure ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Biotech
Series ATotal funding$3.0BJan 2022
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech
Corporate RoundTotal funding$2.3BJun 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ArriVent on Indexed.vc
<a href="https://indexed.vc/companies/arrivent"><img src="https://indexed.vc/api/badge/company/arrivent" alt="ArriVent on Indexed.vc" width="260" height="76" /></a>